cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arcutis Biotherapeutics Inc
1 own
1 watching
Current Price
$16.56
$0.46
(2.86%)
logo-arqt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,008.65M
52-Week High
52-Week High
27.4
52-Week Low
52-Week Low
12.81
Average Volume
Average Volume
0.58M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,008.65M
icon52-Week High27.4
icon52-Week Low12.81
iconAverage Volume0.58M
iconDividend Yield--
iconP/E Ratio--
What does the Arcutis Biotherapeutics Inc do?
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Read More
How much money does Arcutis Biotherapeutics Inc make?
News & Events about Arcutis Biotherapeutics Inc.
Globe Newswire
14days ago
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks)Efficacy was consistent over time across all endpoints, and no ...
Globe Newswire
1month ago
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasisIf approved, ZORYVE would be the first steroid-free topical phosphodiesterase-4 (PDE4) ...
Globe Newswire
1month ago
Study met the primary endpoint and key secondary endpoints, consistent with positive topline results from the INTEGUMENT-1 trial released in NovemberFor the primary endpoint, 28.9% of individuals treated with roflumilast cream 0.15% achieved Investigator Global Assessment (IGA) Success compared to ...
Globe Newswire
1month ago
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver drug deep into the skin to the base of the hair follicle where key alopecia areata inflammation ...
Globe Newswire
2 months ago
Newly published phase 2b trial data show those treated with roflumilast cream had significantly greater improvements in itch compared to those treated with vehicle by Week 2 as assessed by the Worst Itch Numeric Rating Scale (WI-NRS) and Psoriasis Symptom Diary (PSD)Among a subset of participants ...
Frequently Asked Questions
Frequently Asked Questions
What is Arcutis Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Arcutis Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Arcutis Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Arcutis Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arcutis Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Arcutis Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Arcutis Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arcutis Biotherapeutics Inc?
plus_minus_icon
What percentage is Arcutis Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arcutis Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$16.56
$0.46
(2.86%)
logo-arqt
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00